Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Tuesday Brief: Capital Gets Conditional Monday’s session reinforced a “Capital Gets Conditional” regime: multi-year clinical durability (Sarepta) and clear regulatory differentiation (Guardant) are being rewarded,
Last week confirmed a shift from asset acquisition toward structured optionality, with milestone-heavy dealmaking in oncology and immunology accelerating alongside FDA clearances that reinforce momentum
Big Pharma business development and late-stage venture capital converged today around differentiated platforms. Bristol Myers Squibb committed $850 million to tumor-activated T-cell engagers through a
IntraBio’s pivotal Phase 3 success in ataxia-telangiectasia validates a viable registrational path for functional endpoints in ultra-rare disease, while the FDA’s draft guidance on minimal
Celcuity’s Priority Review for gedatolisib establishes a July 17 PDUFA date in HR+/HER2- breast cancer, creating a hard anchor for the competitive landscape in the
U.S. markets return from the MLK holiday today to face the “JPM Bill.” Late Friday, the sector priced nearly $2.5 billion in secondary equity, led
The 44th Annual J.P. Morgan Healthcare Conference is officially in the books. As predicted, Friday saw a massive “clearing event,” with over $2.5 billion in
The 44th Annual J.P. Morgan Healthcare Conference closed today not with a bang, but with a flood of financing paperwork. As the enthusiasm of Day
If Day 2 of the J.P. Morgan Healthcare Conference was about policy and strategy, Day 3 was about operational truth. Vertex cemented its leadership in
JPM Day 2: Obesity’s Volume vs. Value Moment Day 2 of the J.P. Morgan Healthcare Conference crystallized two themes that will define biopharma strategy for
